<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208909</url>
  </required_header>
  <id_info>
    <org_study_id>ZU-XYZ-002</org_study_id>
    <nct_id>NCT01208909</nct_id>
  </id_info>
  <brief_title>Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)</brief_title>
  <official_title>Combined Approach to GBM-resection by 5-ALA and Intraoperative MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the treatment of glioblastoma (GBM) neurosurgical resection of the tumor is usually
      considered a a first step of effective therapy. Radical resection of the tumor is highly
      beneficial to the patient as measured in progression-free survival and overall survival. At
      the same time eloquent areas of the brain have to remain intact to preserve quality of life.

      Both 5-ALA fluorescence and intraoperative MRI are used for intraoperative marking of tumor
      tissue and thereby to improve precision of GBM-Resection.

      We now study whether the combination of 5-ALA fluorescence and intraoperative MRI increases
      the number of sites where tumor tissue can be detected.

      - Trial with surgical intervention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Precision of GBM-Resection Intraoperative marking of tumor tissue Combination of 5-ALA
      fluorescence and intraoperative MRI
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic 5-ALA and MRI for tumor resection</intervention_name>
    <description>diagnostic 5-ALA and MRI for tumor resection</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tumor samples for pathophysiology
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with Glioblastoma multiforme (GBM)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  patients with Glioblastoma multiforme (GBM)

          -  no other tumor types or metastases

        Exclusion criteria:

          -  Allergy against 5-ALA or Porphyrin

          -  Porphyria

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>René L Bernays, MD</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>René L. Bernays, MD</last_name>
    <phone>+41 (0)44 255 11 11</phone>
  </overall_contact>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René L Bernays, MD</last_name>
      <phone>+41 44 25</phone>
      <phone_ext>5111</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>October 21, 2010</last_update_submitted>
  <last_update_submitted_qc>October 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. R. L. Bernays</name_title>
    <organization>University of Zurich</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

